查詢結果分析
來源資料
相關文獻
- Jejunal Gastrointestinal Stromal Tumors with Liver Metastasis: Report of a Case
- Prognostic Factors in Node-Negative Breast Cancer Patients: The Experience in Taiwan
- Postoperative Radiotherapy of Adult Supratentorial High-grade Astrocytoma
- 成人低惡性度顱內星狀細胞瘤之術後放射治療
- Cystic Neuroblastoma with Hepatic Metastasis: Report of One Case
- Detection of Serum Anti-p53 Antibody in Patients with Renal Cell Carcinoma
- 大腸癌之肝臟轉移的手術治療
- Ferrite-Enhanced MR Imaging of Hepatic Metastases: Animal Investigation
- 乳癌預後因子探討--論流式細胞分析儀在乳癌之應用
- Prognostic Factors and Results of Radiotherapy for Brain Stem Gliomas
頁籤選單縮合
題名 | Jejunal Gastrointestinal Stromal Tumors with Liver Metastasis: Report of a Case=空腸的腸胃道基質瘤合併肝臟轉移--病例報告 |
---|---|
作者姓名(中文) | 邱榮彬; 李嘉龍; 黃世鴻; 吳啟華; 陳德芳; | 書刊名 | 輔仁醫學期刊 |
卷期 | 4:2 民95.06 |
頁次 | 頁99-106 |
分類號 | 416.24 |
關鍵詞 | 腸胃道基質瘤; 肝臟轉移; 預後因子; Gastrointestinal stromal tumor; GIST; CD-117; Liver metastasis; Prognostic factor; Imatinib mesylate; |
語文 | 英文(English) |
中文摘要 | 腸胃道基質瘤(GIST)被認為是源自腸胃道的間質性腫瘤。臨床上病患通常以腹部不適,可觸摸到腫塊,或是消化道出血表現。大約70%的腫瘤在胃被發現,20-30%的腫瘤出現在小腸,小於10%在其他腸胃部位,偶爾會在腹膜,網膜的地方被找到。腸胃道基質瘤最常見的轉移部位是肝臟,我們提出一個病例是一位五十三歲的女性,她最初是以解黑便為臨床表現合併腹脹的原因到醫院求診,經檢查後發現是空腸的腸道基質腫瘤出血及合併肝臟轉移情形。腫瘤的大小及細胞分裂指數為最常用的預後評估因子,例如腫瘤大小直徑大於五公分以及高有絲分裂指數(大於5/50HPF)為預後不良。腸胃道基質瘤的標的物(Target)治療是一項重要的突破也帶來相當的益處。 |
英文摘要 | Gastrointestinal stromal tumors (GISTs), previously presumed to be of smooth muscle origin, represent a distinct but heterogeneous group of neoplasms with respect to their molecular etiology and cellular origin. Patients usually present with abdominal discomfort, a palpable mass, or GI bleeding. About 70% of tumors occur in the stomach, 20%~30% in the small intestine, and fewer than 10% in other locations of the GI tract and occasionally in the peritoneum, omentum, and retroperitoneum. The liver is the most common organ of metastasis along with local recurrence and invasion to the peritoneum. Lymph node metastasis is rare. We present a 53-year-old woman who had a jejunal tumor with liver involvement initially showing tarry stool passage. In serial studies, GIST with liver metastasis was the final diagnosis. Tumor size and the mitotic index are the 2most frequently used prognostic factors: a large tumor (>5 cm) and a high mitotic index (>5/50 high power fields) indicate a poor prognosis. A critical breakthrough was recently made in molecularly targeted treatment and prognosis of GISTs. Imatinib mesylate (Gleevec) has been shown to have benefits and encouraging progress. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。